Neuroprotective effects of cannabidiol on dopaminergic neurodegeneration and α-synuclein accumulation in C. elegans models of Parkinson’s disease

Muhammad, Fahim; Liu, Yan; Wang, Ningbo; Zhao, Longhe; Zhou, Yangtao; Yang, Hui; Li, Hongyu

doi:10.1016/j.neuro.2022.09.001

Cited by 18 publications

(12 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Chymotrypsin‐like activity of proteasomes in OW13 was measured using a previously described method (Muhammad et al, 2022). With brief changes, transgenic OW13 worms were incubated with NGM/OP50/REO at 20, 30, 40, and 50 μg/ml for 72 h at 20°C.…”

Section: Methodsmentioning

confidence: 99%

See 1 more Smart Citation

Rose essential oil diminishes dopaminergic neuron degenerations and reduces α‐synuclein aggregation in Caenorhabditis elegans models of Parkinson's disease

Muhammad

Liu

Wang

et al. 2023

Phytotherapy Research

Self Cite

View full text Add to dashboard Cite

Parkinson's disease (P.D.) is the second most progressive neurodegenerative disorder in the elderly. Degeneration of dopaminergic (DA) neurons and α-synuclein (α-Syn) accumulated toxicity is the major contributor to this disease. At present, the disease has no effective treatment. Many recent studies focus on identifying novel therapeutics that provide benefits to stop the disease progression in P.D. patients. Screening novel and effective drugs in P.D. animal models is time-and cost-consuming. Rose Essential Oil (REO) extracted from Rosa Rugosa species (R. Setate Â R. Rugosa). REO contains Citronellol, Geraniol, and Octadiene that possess anti-Aβ, anti-oxidative, and anti-depression-like properties, but no reports have defined the REO effect on P.D. yet. The present study examines the REO neuroprotective potential in transgenic Caenorhabditis elegans P.D. models. We observed that REO reduced α-Syn aggregations and diminished DA neuron degenerations induced by 6-OHDA, reduced food-sensing behavioural disabilities, and prolonged the lifespan of the nematode. Moreover, REO augmented the chymotrypsin-like proteasome and SOD-3 activities. Further, we observed the anti-oxidative role of REO by reducing internal cells ROS.Together, these findings supported REO as an anti-PD drug and may exert its effects by lowering oxidative stress via the anti-oxidative pathway.

show abstract

Section: Methodsmentioning

confidence: 99%

“…Chymotrypsin-like activity of proteasomes in OW13 was measured using a previously described method (Muhammad et al, 2022). With…”

Section: Reo and The Chymotrypsin-like Proteasome Activitymentioning

confidence: 99%

Rose essential oil diminishes dopaminergic neuron degenerations and reduces α‐synuclein aggregation in Caenorhabditis elegans models of Parkinson's disease

Muhammad

Liu

Wang

et al. 2023

Phytotherapy Research

Self Cite

View full text Add to dashboard Cite

show abstract

“…Researchers have conducted investigations into the treatment effects of CBD/THC for age-related diseases such as Alzheimer’s disease [ 173 , 174 , 175 , 176 , 177 ], dementia [ 178 , 179 ], and Parkinson’s disease [ 180 , 181 , 182 , 183 , 184 ]. However, most of these studies either focus on the PD of CBD/THC and the clinical endpoint of the disease or combine all age groups when analyzing the PK results.…”

Section: Cbd/thc Studies In Special Populationsmentioning

confidence: 99%

CBD and THC in Special Populations: Pharmacokinetics and Drug–Drug Interactions

Qian,

Beers,

Jackson

et al. 2024

Pharmaceutics

View full text Add to dashboard Cite

Cannabinoid use has surged in the past decade, with a growing interest in expanding cannabidiol (CBD) and delta-9-tetrahydrocannabinol (THC) applications into special populations. Consequently, the increased use of CBD and THC raises the risk of drug–drug interactions (DDIs). Nevertheless, DDIs for cannabinoids, especially in special populations, remain inadequately investigated. While some clinical trials have explored DDIs between therapeutic drugs like antiepileptic drugs and CBD/THC, more potential interactions remain to be examined. This review summarizes the published studies on CBD and THC–drug interactions, outlines the mechanisms involved, discusses the physiological considerations in pharmacokinetics (PK) and DDI studies in special populations (including pregnant and lactating women, pediatrics, older adults, patients with hepatic or renal impairments, and others), and presents modeling approaches that can describe the DDIs associated with CBD and THC in special populations. The PK of CBD and THC in special populations remain poorly characterized, with limited studies investigating DDIs involving CBD/THC in these populations. Therefore, it is critical to evaluate potential DDIs between CBD/THC and medications that are commonly used in special populations. Modeling approaches can aid in understanding these interactions.

show abstract

“…CBD treatment is demonstrated with the reduction in Aβ aggregation, tau hyperphosphorylation and neuroinflammation, enhancement of autophagy and attenuation of memory deficits in mouse and C. elegans models of AD (Alali et al, 2021; Cheng et al, 2014; Khodadadi et al, 2021; Watt et al, 2020; Zhang et al, 2022). The compound is also found to ameliorate dopaminergic neuron degeneration, neuroinflammation, exert inhibition to α‐synuclein aggregation and improve motor functions in C. elegans , rat and mouse models of PD (Giuliano et al, 2021; Muhammad et al, 2022; Zhao et al, 2022). The effective dose of CBD can be suggested to be between 5 and 50 mg/kg i.p.…”

Section: Phyto‐compounds and Their Neuroprotective Effects In Ad And ...mentioning

confidence: 99%

Therapeutic considerations of bioactive compounds in Alzheimer's disease and Parkinson's disease: Dissecting the molecular pathways

Phukan,

Roy,

Gahatraj

et al. 2023

Phytotherapy Research

View full text Add to dashboard Cite

Leading neurodegenerative diseases Alzheimer's disease (AD) and Parkinson's disease (PD) are characterized by the impairment of memory and motor functions, respectively. Despite several breakthroughs, there exists a lack of disease‐modifying treatment strategies for these diseases, as the available drugs provide symptomatic relief and bring along side effects. Bioactive compounds are reported to bear neuroprotective properties with minimal toxicity, however, a detailed elucidation of their modes of neuroprotection is lacking. The review elucidates the neuroprotective mechanism(s) of some of the major phyto‐compounds in pre‐clinical and clinical studies of AD and PD to understand their potential in combating these diseases. Curcumin, eugenol, resveratrol, baicalein, sesamol and so on have proved efficient in countering the pathological hallmarks of AD and PD. Curcumin, resveratrol, caffeine and so on have reached the clinical phases of these diseases, while aromadendrin, delphinidin, cyanidin and xanthohumol are yet to be extensively explored in pre‐clinical phases. The review highlights the need for extensive investigation of these compounds in the clinical stages of these diseases so as to utilize their disease‐modifying abilities in the real field of treatment. Moreover, poor pharmacokinetic properties of natural compounds are constraints to their therapeutic yields and this review suggests a plausible contribution of nanotechnology in overcoming these limitations.

show abstract

Neuroprotective effects of cannabidiol on dopaminergic neurodegeneration and α-synuclein accumulation in C. elegans models of Parkinson’s disease

Cited by 18 publications

References 43 publications

Rose essential oil diminishes dopaminergic neuron degenerations and reduces α‐synuclein aggregation in Caenorhabditis elegans models of Parkinson's disease

Rose essential oil diminishes dopaminergic neuron degenerations and reduces α‐synuclein aggregation in Caenorhabditis elegans models of Parkinson's disease

CBD and THC in Special Populations: Pharmacokinetics and Drug–Drug Interactions

Therapeutic considerations of bioactive compounds in Alzheimer's disease and Parkinson's disease: Dissecting the molecular pathways

Contact Info

Product

Resources

About